Innovent Biologics, Inc. announced that results of a Phase 2 clinical trial of mazdutide (Innovent R&D code: IBI362), a glucagon-likeptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese patients with overweight or obesity were published in Nature Communications. Professor Linong Ji, the leading principal investigator of the study, Peking University People's Hospital, stated, "As a chronic disease with complex underlying causes, obesity is one of the leading risk factors of type 2 diabetes, fatty liver, cardiovascular and cerebrovascular diseases, joint diseases, sleep apnea in addition to cancers. obesity requires increased public awareness of long-term treatment and management with effective and science-backed approaches.

Currently, the phase 3 study of mazdutide 4 mg and 6 mg in Chinese patients with overweight or Obesity (GLORY-1) are underway, which will provide critical clinical evidence in large sample size. The company recently also initiated the Phase 3 study to provide higher dose mazdutide 9mg for population with higher baseline of obesity. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies, as well as reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes and liver fat content, as well as improving insulin sensitivity, bringing multiple metabolic benefits.

Currently, three key phase 3 studies of mazdutide4 mg and 6 mg in Chinese Patients with overweight or obesity (GLORY-1) and type 2 diabetic (DREAM-1 and DREAM-2) subjects are underway. The Phase 3 clinical study of mazdutides 9 mg in Chinese subjects with obesity was initiated in the end of 2023.